Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

1 Day TEVA -0.62% DJIA -0.75% S&P 500 -0.50% Health Care/Life Sciences 0.29% ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...